YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Carlsmed CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit a…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest analyst work on Carlsberg resets the fair value anchor from DKK 1,045 to about DKK 1,0…
Key Points Interested in Carlsmed, Inc.? Here are five stocks we like better. Carlsmed's Q2 revenue rose 57% year over year to $18.9 million, driven by higher adoption of its aprevo lumbar platform and newer cervical offering. The surgeon…
Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $1.47 per share a year ago. These figures are adjusted for non-recurring items. This…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Align Technology (ALGN) is a stock that can certainly grab the attention of many investors, but do its r…
Earnings Call Insights: Carlsmed (CARL) Q1 2026 MANAGEMENT VIEW * "We delivered strong revenue of $16.1 million, representing growth of 58% over the prior year." (Co-Founder, Chairman, CEO & President Michael Cordonnier) * "Operationally,…
Carlsmed logo Key Points Revenue and outlook: Q1 revenue was $16.1 million, up 58% year‑over‑year, and management raised full‑year 2026 guidance to $72–$77 million (about 48% growth at the midpoint); gross margin was ~77% while GAAP net lo…
Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.47 per share a year ago. These figures are adjusted for non-recurring items. This…
Image source: The Motley Fool. Date Tuesday, May 5, 2026 at 4:30 p.m. ET Call participants Chairman & Chief Executive Officer — Michael Cordonnier Chief Financial Officer — Leonard Greenstein Vice President, Investor Relations — Stephanie…
Pepsi Picks Its Winner and Royal Unibrew Pays the Price - Moby THE GIST PepsiCo has reshuffled its Nordic bottling network, handing a major win to Carlsberg and leaving Royal Unibrew with a sizable hole in its business. The numbers are not…
CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on A…
Carlsmed logo Key Points aprevo Technology Platform delivers patient-specific 3D surgical planning, on‑demand 3D‑printed implants and sterile single‑use instruments across the pre/intra/post‑op workflow; the company has expanded into cervi…
Earnings Call Insights: Carlsmed, Inc. (CARL) Q4 2025 MANAGEMENT VIEW * CEO Michael Cordonnier reported, "2025 was a rapid growth year for Carlsmed and I could not be prouder of what our team has accomplished to advance our mission of impr…
CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 202…
Carlsmed CARL recently announced the U.S. commercial launch of its aprevo Technology Platform for cervical fusion procedures at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting in Washington, D.C. The launch marks the company…
CARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion surgeries. Surgeons involved…
Investing.com -- European beverage stocks will enter 2026 offering broad valuation appeal after another year of weak share price performance, though the sector remains cheap for a reason and will require clearer delivery on earnings to unl…
CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting at the 37th Annual Piper Sandler Health…
Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “…
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial res…
Carlsberg (CPSE:CARL B) shares have quietly shifted over the past month, down nearly 4%. This recent move invites a closer look at how the company is performing in today's evolving beverage market. See our latest analysis for Carlsberg. Lo…
Carlsberg Britvic, in partnership with PepsiCo, recently announced an exclusive UK distribution agreement for Poppi, a US prebiotic soda brand, and is exploring further portfolio expansion with Mexican-style beer and functional soft drinks…
Carlsmed CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appoint…
CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of J…
* Carlsmed (NASDAQ:CARL [https://seekingalpha.com/symbol/CARL]) added to the Russell 2000 Index effective after market close on September 22, 2025. * Inclusion follows Carlsmed’s IPO in July 2025, part of Q3 index rebalancing. * Source: Pr…
CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after…
The stock markets are at record highs, having shown a solid recovery from their sharp losses in April. Year-to-date, the S&P 500 is up 11% and the NASDAQ is up 13.5%, reflecting continued positive sentiment. Elevate Your Investing Strategy…
Carlsberg (CPSE:CARL B) has been on the radar lately as its shares have drifted lower in recent weeks, even though there has been no headline-grabbing event to drive the moves. Sometimes, it is the subtle shifts that spark the biggest ques…
(RTTNews) - Carlsmed, Inc. (CARL) released Loss for second quarter of -$6.77 million The company's earnings totaled -$6.77 million, or -$1.47 per share. This compares with -$6.28 million, or -$1.55 per share, last year. The company's reven…
Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pion…
Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pion…
Carlsmed Inc. (NASDAQ:CARL), an AI-powered innovator in spine surgery, is poised for significant growth following key advancements and strong analyst projections. The company recently secured additional Medicare reimbursement for its aprev…
[Doctor check and diagnose the human spine on blurred background] Mohammed Haneefa Nizamudeen/iStock via Getty Images Medical technology firm Carlsmed (NASDAQ:CARL [https://seekingalpha.com/symbol/CARL]) was initiated with a Buy at Truist…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: UBS upgraded CVS Health(CVS) to Buy from N…
Investing.com - Piper Sandler initiated coverage on Carlsmed Inc (NASDAQ:CARL) with an Overweight rating and a price target of $18.00 on Monday. The company, currently valued at $360 million, has shown strong gross margins of 74% despite n…
Investing.com - Goldman Sachs initiated coverage on Carlsmed Inc (NASDAQ:CARL) with a Buy rating and a $19.00 price target, representing approximately 40% upside potential from current levels. According to InvestingPro data, the stock’s RS…